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I N T R O D U C T I O N
Cardiovascular disease (CVD) which includes coronary artery disease (CAD), 
stroke and peripheral vascular disease, is the leading cause of death in developed and 
in most developing countries1. The last decades have shown an impressive reduction 
in the rate of death from cardiac disease, both due to disease-specific therapies but 
mainly due to the widespread implementation of primary and secondary prevention 
strategies, that target modifiable risk factors2-4. The increasing prevalence of type 2 
diabetes mellitus and obesity will probably have a negative impact on CVD preven-
tion and treatment.
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education 
Program (NCEP) has provided clinicians with recommendations regarding primary 
and secondary prevention of cardiovascular disease5, based on Framingham risk score. 
Nevertheless, such a risk factor assessment would only predict 60-65% of cardiovas-
cular events, and a substantial number of episodes occur in patients categorized in 
the low or moderate risk categories6, who would not be considered candidates for the 
most aggressive prevention strategies. Such an observation has led investigators to 
search for novel risk factors, as well as new means of diagnosing subclinical coronary 
artery disease in order to identify more subjects that could benefit from intensive risk 
factor modification.
High-sensitivity C-reactive protein (hsCRP) is an inflammatory biomarker which 
has been shown to be a significant contributor to the prediction of CAD7. The re-
cently published JUPITER study8, has renewed interest on the importance of hsCRP, 
since the results showed an impressive reduction of cardiovascular risk with the use 
of a statin not for hyperlipidemia but for elevated hsCRP levels. On the other hand, 
coronary artery calcium (CAC) is a sensitive indicator of atherosclerosis and has also 
been studied in risk stratification9. The present review will focus on the value of the 
above indices as a means to better identify individuals at high risk in order to offer 
them appropriate prevention measures.
A T P  I I I  G U I D E L I N E S
ATP III guidelines have been the most widely used tool for individual risk assess-
ment. They are based on the Framingham risk score, which takes into account age, 
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gender, family history of premature CAD, smoking status, 
blood pressure levels, as well as total and HDL cholesterol. 
According to these criteria, patients are categorized into low 
risk, if their calculated 10-year risk is less than 10%, and high 
risk, if they have known CAD or a CAD-equivalent such as 
diabetes mellitus, symptomatic carotid disease, abdominal 
aortic aneurysm, peripheral vascular disease or if their calcu-
lated 10-year risk exceeds 20%. The intermediate risk category 
has been further divided into moderate risk, for those that have 
two or more of the above risk factors and a 10-year risk less 
than 10%, and moderately high risk, if the 10-year risk is 10-
20%5. Only the high risk patients would be offered aggressive 
preventive measures and yet a great number of cardiovascular 
events happen in the intermediate risk patients. In particular, 
a study which included previously asymptomatic young adults, 
hospitalized for a first myocardial infarction, showed that 75% 
would not have been candidates for statin therapy, accord-
ing to ATP III guidelines10. There is also evidence that the 
Framingham risk score does not perform well in women11. As 
the treatment of all intermediate risk patients would not be 
cost-efficient, the need for further risk stratification in order 
to improve patient selection is evident.
One of the innate drawbacks of the Framingham and 
other risk models is that they estimate a patient’s risk based 
on population studies, without taking into account the actual 
presence of atherosclerotic disease in a particular patient. Only 
an imaging technique with adequate sensitivity and specificity 
could assist in this matter by providing direct evidence of the 
absence or presence, as well the extent of atherosclerosis.
C O R O N A R Y  A R T E R Y  C A L C I U M  ( C A C ) 
S C O R E
Atherosclerotic plaques are known to acquire calcium 
via a process that resembles normal bone formation. The 
lipid core is the first to be calcified and although the whole 
mechanism is not known, it seems that the apoptotic cells 
play the role of nuclei in order to start the accumulation of 
calcium12. The correlation between calcification and vascular 
disease has been known for many years and the first report 
to demonstrate the diagnostic and prognostic significance of 
CAC was published in 198013. Since then, the development of 
Electron- Beam Computed Tomography (EBCT) and more 
recently of Multi-Detector Computed Tomography (MDCT), 
has permitted a quantitative assessment of coronary artery 
calcium, providing accurate and reproducible data9,14.
The most widely used tool for quantification of coronary 
calcium is the Agatston score15. EBCT was the first CT 
technique to be used and although modern technology has 
allowed improved visualization of the beating heart, with 
little or no motion artifact through MDCT, most of the 
data regarding CAC has been from studies utilizing EBCT. 
Due to the important technical differences between the two 
modes, there is some debate whether the results of one can 
be compared to those of the other16. Although a direct head-
to-head comparison between the two methods would no be 
feasible, there is evidence showing that their scores have a 
similar significance17.
Calcium is not present in normal coronary arteries. 
Therefore, coronary calcification with very rare exceptions is a 
marker of underlying atherosclerosis. The close association of 
CAC and atherosclerotic burden was studied with histopathol-
ogy and intravascular ultrasound18,19. Although the presence 
of calcium denotes atherosclerosis, it does not necessarily 
mean obstructive lesions. In the aforementioned autopsy study, 
the authors found that the burden of non-calcified plaques 
was five times higher than the calcified ones. There lies the 
main difference between CAC scoring and the various forms 
of stress testing, as the latter aim to identify flow-limiting 
disease. The prognosis of coronary artery disease, however, 
is more closely related to the extent of atherosclerosis than to 
a particular stenosis severity20,21.
Coronary artery calcium scores tend to be higher in older 
patients, which correlates with advanced CAD, and also in 
men, compared to women22. The most commonly used clas-
sification for CAC score is as follows23,24:
0: no identifiable disease
<100: mild disease
100-400: moderate disease
>400: severe disease
A large cohort study of more than 6000 initially asymp-
tomatic adults who were followed up for a median of 3.8 
years25, showed that a higher CAC score is associated with 
higher events rate, although, even with the high scores the 
event rate was only 1% per year. The predictive role of CAC 
score in this Multi-Ethnic Study of Atherosclerosis (MESA) 
was demonstrated for whites as well as for blacks, Hispanics 
and Chinese. Despite a higher prevalence of CAC and higher 
scores in white patients, it appears that CAC is an important 
marker of risk in all races.
With respect to age, it should be noted that younger adults 
may have atherosclerotic plaques with no calcification with 
the obvious risk of rupture, to create an acute coronary event. 
Yet, any degree of calcification, even a mild score, would 
place them in a high risk percentile, compared to age- and 
sex-matched controls. Framingham risk calculation has the 
same limitations, since the 10-year risk in a younger adult 
would not be high even in the existence of multiple risk factors, 
and some have proposed that calculating the life-time risk in 
this age group would be more appropriate26.
Although, as already mentioned, the purpose of CAC 
scoring is not the identification of obstructive disease, there 
are data showing that a low CAC score is associated with a 
low probability of abnormal SPECT27. The above study also 
showed that CAC score may be raised even in the absence 
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of perfusion abnormalities. Another study of asymptomatic 
individuals undergoing both SPECT and EBCT, showed that 
CAC predicted an abnormal SPECT regardless of age or sex, 
and the higher the CAC score the more likely it was to have 
a perfusion abnormality28.
CAC scoring was also shown to help in the prognostic 
evaluation of asymptomatic individuals and the risk of death 
increased proportionally to the baseline calcium scores29. 
Moreover, data analysis utilizing both traditional risk factors 
and CAC score showed that coronary calcium provides inde-
pendent incremental information in addition to traditional risk 
factors in the prediction of all-cause mortality. A meta-analysis 
of four trials24 concluded that despite the observed variability 
in the relative risk estimate between studies, CAC score is an 
independent predictor of coronary heart disease events.
CAC score has been proven to be predictive of adverse CV 
events in the elderly. The prospective Rotterdam study which 
included CAC scoring and traditional risk factor measurement 
showed an improved cardiovascular risk prediction in the older 
age group30. Moreover, a more recent study, which included a 
large number of patients over 70 years, showed that increasing 
CAC score was predictive of decreased survival rates in all 
age groups, even in the elderly31. Of equal importance was the 
observation that more than 40% of the elderly patients were 
reclassified to a lower or higher risk category using the CAC 
score, compared to their original classification based on the 
Framingham risk score.
An increased degree of calcification of the coronary arter-
ies has been demonstrated in subjects with type 1 and type 2 
diabetes mellitus and insulin resistance32,33. A study comparing 
diabetic and non-diabetic patients, undergoing CAC scoring, 
showed a higher mortality rate in the former patients, for any 
given degree of CAC score34.
Several studies have also examined the utility of CAC 
in women. Raggi et al showed that CAC scores were lower 
in women compared to men, but its addition to traditional 
risk calculation offered incremental prognostic value35. A 
meta-analysis, comparing the usefulness of coronary artery 
calcium in men and women, concluded that CAC is equally 
accurate in estimating all-cause mortality and CAD death in 
both genders36.
C A C  S C R E E N I N G  A N D  F R A M I N G H A M 
R I S K  S C O R E  ( F R S )
Taking into consideration all of the above data, the ques-
tion is who should be screened using the CAC score. The 
Bayesian theorem provides a useful start point, as the post-test 
probability of events depends also on the pre-test likelihood 
of the patient’s risk. In other words, if a patient has an initially 
low probability of having CAD, the addition of CAC would 
obviously increase the risk but even so, the resulting post-test 
risk would still be low. Similarly, patients classified as high risk 
according to ATP III, would still merit preventive measures 
even if their CAC score was low.
There are reports, showing that CAC scoring in low risk 
subjects is not useful in modifying risk prediction37,38. The 
study by Greenland et al37, concluded that a high CAC score 
can significantly modify risk prediction in patients with an 
intermediate traditional FRS of 10-20%. In other words, the 
absence of coronary calcium might shift these patients to a 
low-risk category, while a high CAC would indicate a high 
level of risk. On the contrary, CAC was not useful in patients 
with FRS less than 10% or more than 20%, and the clinical 
approach to those patients would not be modified.
Therefore it appears prudent to use CAC scoring se-
lectively, in those patients with an intermediate FRS. The 
authors of the ACCF/AHA expert consensus document on 
coronary artery calcium scoring, stated that intermediate-risk 
FRS patients with a CAC score greater than or equal to 400 
would have an increased risk of adverse CV events, enough 
to place them in the high-risk category of CAD- equivalent, 
thus warranting aggressive preventive measures14.
I S  C A C  T E S T I N G  S A F E ?
Obviously, there is a radiation burden associated with 
the use of both EBCT scanning (0.6 to 1 mSv) and MDCT 
(0.9 to 2 mSv) that needs to be taken into account, especially 
if serial testing is considered to monitor CAD progression9. 
In comparison, a chest radiograph has a dose of 0.01 to 0.02 
mSv. It has been reported that a dose of 2.3 mSv can increase 
the probability of cancer39. Thus, the use of CAC scoring in 
a widespread population would need to take radiation safety 
into account.
Therefore, the question arises whether a novel marker 
of CAD such as high-sensitivity C-reactive protein (hs-
CRP) might be a cheaper, safer and easier way to reclassify 
intermediate-risk patients and thus modify their risk factor 
modification.
H I G H - S E N S I T I V I T Y  C R P  ( H S - C R P )  
A N D  T H E  J U P I T E R  T R I A L
There are sufficient data both from experimental and 
population based studies, to show that atherosclerosis has 
an inflammatory component40. Inflammation not only par-
ticipates in atheroma formation but also contributes to the 
vulnerability and plaque rupture or erosion41. CRP is an acute 
phase protein, secreted by the liver, in response to systemic 
cytokines such as interleukin 1β and 6 and tumor necrosis 
factor α. Whether CRP has a pathogenetic role in the develop-
ment of cardiovascular disease, or is an non specific marker 
of the acute phase response to inflammation, is an unresolved 
question42,43.
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Traditional assays, used for patients with infectious or 
inflammatory disorders, have a detection limit of 3 to 5 mg/L 
which is above the levels of most healthy subjects. High-sen-
sitivity methods have been developed that detect levels as 
low as 0.3mg/L and these have been used for cardiovascular 
risk stratification. A statement from the Centers for Disease 
Control and Prevention and the American Heart Association 
(CDC/AHA) concluded that the average of two measure-
ments, two weeks apart, rather than a single one should be used 
and the cutoff values for low, average and high levels should be 
less than 1 mg/L, 1 to 3 mg/L and above 3 mg/L respectively. 
There is definitely variability in hsCRP levels over time, which 
reflects the change in the systemic inflammatory status. This 
was demonstrated in a study of stable ischemic heart disease 
patients, where the second measurement resulted in 40% of 
the patients changing risk category44.
High-sensitivity CRP has been proposed as a useful bio-
marker for the prediction of CVD risk stratification. A useful 
biomarker is one that is easy to obtain, accurate, reproduc-
ible, internationally standardized, adds to clinical knowledge, 
provides risk information, on top of other known predictors 
and helps in risk classification and patients’ therapy45. Many 
studies have shown that increased levels of hs-CRP are as-
sociated with an increased risk of cardiovascular events even 
after adjustment for traditional risk factors46. The multivariate 
analysis of hsCRP and traditional risk factors, to assess their 
predictive value on CV risk has revealed that the strength of 
hs-CRP is similar to the one of LDL, systolic blood pressure 
and cigarette smoking. Moreover, several trials have shown 
that the addition of hs-CRP to other risk factors, results in 
reclassification of a significant number of patients to a differ-
ent risk category47. Similar trials have shown the association of 
hsCRP with the development of type 2 diabetes mellitus and 
metabolic syndrome as well as an increased risk of stroke46.
The JUPITER trial was designed to investigate the effect 
of statin treatment in a population with only average LDL 
levels but with elevated hsCRP48. Patients with an LDL level 
below 130 mg/dl and a CRP of at least 2 mg/dl were randomly 
assigned to treatment with rosuvastatin 20mg or placebo. Al-
though the trial was estimated to last 4 years, it was terminated 
early, after approximately 2 years of follow-up due to the ben-
eficial effect of rosuvastatin on the primary endpoint ( cardio-
vascular death, myocardial infarction, stroke, hospitalization 
for unstable angina or arterial revascularization) and all cause 
mortality. The cumulative incidence of cardiovascular events 
was reduced by 44% and all cause mortality was reduced by 
approximately 20%. The benefit of statin treatment was seen in 
various subgroups such as women, patients with metabolic syn-
drome and the elderly. Although rosuvastatin demonstrated 
an excellent safety profile, similar to other statins currently 
used, an increased incidence of physician reported diabetes 
was shown on the JUPITER trial. This finding has also been 
observed in other statin trials49,50.
Other studies such as the CARE trial have shown that 
statins lower hsCRP levels51. This is believed to be part of the 
multiple antiatherogenic effects of statins which have been 
shown to have an anti-inflammatory action. Moreover, statins 
reduce CRP levels in a manner similar to LDL, i.e. the more 
potent drugs have the greatest effects on hsCRP lowering.
The JUPITER trial was the first to demonstrate that a 
much larger subset of patients may be eligible for statin therapy 
in primary prevention. A simple and reproducible marker such 
as hsCRP can be utilized to discriminate a higher risk category 
than the one estimated by the Framingham risk score. These 
patients might also benefit not only from statin treatment but 
also from low-dose aspirin as has already been shown in the 
Physicians Health Study52. The number needed to treat to 
prevent a CV event in the JUPITER trial was calculated to be 
25, which is acceptable and cost effective for primary preven-
tion. Moreover, many studies have shown that the best results 
are reached in high-risk patients on statin treatment who 
achieve both LDL and hsCRP reductions53,54. Thus, hsCRP 
could also serve as a follow-up marker of cardiovascular risk 
reduction, and potentially as an important therapeutic goal 
beyond LDL.
C O N C L U S I O N
Cardiovascular diseases continue to be the leading cause 
of death in the developed world. A better risk prediction is 
definitely needed to lower morbidity and mortality by primary 
prevention measures. The effects of Framingham risk score 
calculation can be improved by both hsCRP measurement and 
coronary artery calcium scoring. More trials are needed in 
order to further estimate and compare their relative efficacy 
in improving risk estimation especially in the intermediate 
risk patients who need it more.
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